

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 401/04, 409/14, 401/14, A61K 31/505		A1	(11) International Publication Number: WO 94/26733 (43) International Publication Date: 24 November 1994 (24.11.94)
(21) International Application Number: PCT/GB94/00999 (22) International Filing Date: 9 May 1994 (09.05.94) (30) Priority Data: 9309573.5 10 May 1993 (10.05.93) GB		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CARLING, William, Robert [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). COLLINS, Ian, James [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LEESON, Paul, David [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). ROWLEY, Michael [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: THOMPSON, John; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		Published With international search report.	
(54) Title: PYRIMIDINE DERIVATIVES			
(57) Abstract A class of substituted pyrimidine derivatives are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system, in particular schizophrenia.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

PYRIMIDINE DERIVATIVES

This invention relates to a particular class of
5 six-membered heteroaromatic compounds. More particularly, the invention is concerned with substituted pyrimidine derivatives which are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of
10 the dopamine system, including schizophrenia, depression, nausea, Parkinson's disease, tardive dyskinesias and extrapyramidal side-effects associated with treatment by conventional neuroleptic agents, neuroleptic malignant syndrome, and disorders of hypothalamic-pituitary function such as hyperprolactinaemia and amenorrhoea.
15

Upper gastrointestinal tract motility is believed to be under the control of the dopamine system. The compounds according to the present invention may thus be of use in the prevention and/or treatment of
20 gastrointestinal disorders, and the facilitation of gastric emptying.

Dependence-inducing agents such as cocaine and amphetamine have been shown to interact with the dopamine system. Compounds capable of counteracting this effect,
25 including the compounds in accordance with the present invention, may accordingly be of value in the prevention or reduction of dependence on a dependence-inducing agent.

Dopamine is known to be a peripheral vasodilator; for example, it has been shown to exert a dilatory effect on the renal vascular bed. This implies that the compounds of the present invention may be beneficial in controlling vascular blood flow.

The localisation of dopamine receptor mRNA in
35 rat heart and large vessels has been noted. This suggests a role for dopamine receptor ligands in


- 2 -

controlling cardiovascular function, either by affecting cardiac and smooth muscle contractility or by modulating the secretion of vasoactive substances. The compounds according to the present invention may therefore be of assistance in the prevention and/or treatment of such conditions as hypertension and congestive heart failure.

Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine D₁ receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D₂ receptor subtype, and at least one form of the D₃ receptor subtype, have also been discovered. More recently, the D₄ (Van Tol *et al.*, Nature (London), 1991, 350, 610) and D₅ (Sunahara *et al.*, Nature (London), 1991, 350, 614) receptor subtypes have been described.

The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes within the body, are accordingly of use in the treatment and/or prevention of disorders of the dopamine system.

The present invention accordingly provides a compound of formula I, or a salt thereof or a prodrug thereof:



(I)

wherein


Q represents a substituted five- or six-membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole heteroatom and is linked to the pyrimidine ring via a carbon atom;

- 3 -


R^1 represents hydrogen, halogen, C_{1-6} alkyl, hydroxy or C_{1-6} alkoxy;

R^2 represents hydrogen, halogen, C_{1-6} alkyl, $-OR^a$ or $-NR^aR^b$; and


5 A represents a group of formula (i), (ii) or (iii):



(i)



(ii)



(iii)


in which Z represents oxygen, sulphur or NH;

20 R^3 , R^4 and R^5 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-OR^a$, $-SR^a$, $-SOR^a$, SO_2R^a , $-SO_2NR^aR^b$, $-NR^aR^b$, $-NR^aCOR^b$, $-NR^aCO_2R^b$, $-COR^a$, $-CO_2R^a$ or $-CONR^aR^b$; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

25 The monocyclic heteroaliphatic ring Q in the compounds of formula I above represents a substituted pyrrolidinyl or piperidinyl moiety linked through carbon. Examples of suitable rings include the moieties of formula Qa to Qe:

- 4 -



wherein one of R⁶ and R⁷ represents hydrocarbon or a heterocyclic group, and the other of R⁶ and R⁷ represents hydrogen, hydrocarbon or a heterocyclic group.

A particular monocyclic heteroaliphatic ring represented by the substituent Q in formula I is the ring of structure Qa above.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable

- 5 -

salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

5 The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, 10 aryl and aryl(C₁₋₆)alkyl.

15 The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ 20 heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

25 Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.

30 Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

35 Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

- 6 -

Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Particular aryl groups include phenyl and 5 naphthyl.

Particular aryl(C₁-6)alkyl groups include benzyl, naphthylmethyl, phenethyl and phenylpropyl.

Suitable heterocycloalkyl groups include 10 azetidinyl, pyrrolidyl, piperidyl, piperazinyl and morpholinyl groups.

Suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and 15 thiadiazolyl groups.

Particular heteroaryl(C₁-6)alkyl groups include pyridylmethyl and pyrazinylmethyl.

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups 20 selected from C₁-6 alkyl, adamantyl, phenyl, halogen, C₁-6 haloalkyl, C₁-6 aminoalkyl, trifluoromethyl, hydroxy, C₁-6 alkoxy, aryloxy, keto, C₁-3 alkylenedioxy, nitro, cyano, carboxy, C₂-6 alkoxy carbonyl, C₂-6 25 alkoxy carbonyl(C₁-6)alkyl, C₂-6 alkylcarbonyloxy, arylcarbonyloxy, C₂-6 alkylcarbonyl, arylcarbonyl, C₁-6 alkylthio, C₁-6 alkylsulphanyl, C₁-6 alkylsulphonyl, arylsulphonyl, -NR^VR^W, -NR^VCOR^W, -NR^VCO₂R^W, -NR^VSO₂R^W, -CH₂NR^VSO₂R^W, -NHCONR^VR^W, -CONR^VR^W, -SO₂NR^VR^W and -CH₂SO₂NR^VR^W, in which R^V and R^W independently represent 30 hydrogen, C₁-6 alkyl, aryl or aryl(C₁-6)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.

The present invention includes within its scope 35 prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of

- 7 -

the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for 5 example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to 10 the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

15 Suitably, the substituent R¹ represents hydrogen or C₁₋₆ alkyl, especially hydrogen or methyl.

Suitable values for the substituent R² include hydrogen, halogen, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, amino, C₁₋₆ alkylamino and di(C₁₋₆)alkylamino.

20 Particular values of R² include chloro and amino.

Suitably, Z is sulphur.


Suitable values for the substituents R³, R⁴ and 25 R⁵ include hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy and C₂₋₆ alkylcarbonyl. Particular values include hydrogen, methyl, ethyl, isopropyl, methoxy and chloro. Suitably, at least one of R³, R⁴ and R⁵ is other than hydrogen.

30 Suitable values for the substituents R⁶ and R⁷ include C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, any of which groups may be optionally substituted. In addition, one of R⁶ and/or R⁷ may represent hydrogen. Examples of suitable substituents on 35 the groups R⁶ and/or R⁷ include C₁₋₆ alkyl, halogen, C₁₋₆ alkoxy, nitro and cyano.

- 8 -

Particular values of R⁶ and R⁷ include hydrogen, allyl, cyclopropylmethyl, cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl, dichlorobenzyl, methoxy-benzyl, nitro-benzyl, cyano-benzyl, 5 naphthylmethyl, phenethyl and phenylpropyl, provided that at least one of R⁶ and R⁷ is other than hydrogen. Suitably, one of R⁶ and R⁷ represents hydrogen, and the other of R⁶ and R⁷ is other than hydrogen. Preferably, R⁷ represents hydrogen and R⁶ is other than hydrogen.

10 A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof:



(IIA)

wherein

R¹¹ represents hydrogen or C₁₋₆ alkyl;
25 R¹² represents hydrogen, halogen, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, amino, C₁₋₆ alkylamino or di(C₁₋₆)alkylamino;
R¹³ represents hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C₁₋₆ alkylamino,
30 di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy or C₂₋₆ alkylcarbonyl; and
R¹⁶ represents C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl or aryl(C₁₋₆)alkyl, any of which groups may be optionally substituted.

- 9 -

Examples of suitable substituents on the group R¹⁶ include one or more of C₁₋₆ alkyl, halogen, C₁₋₆ alkoxy, nitro and cyano.


Particular values of R¹⁶ with reference to formula IIA above include allyl, cyclopropylmethyl, cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl, dichlorobenzyl, methoxy-benzyl, nitro-benzyl, cyano-benzyl, naphthylmethyl, phenethyl and phenylpropyl.

Suitably, R¹¹ represents hydrogen or methyl.

Suitable values of R¹² include hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and amino, especially chloro or amino.

Particular values of R¹³ include hydrogen, chloro, methyl, ethyl, isopropyl and methoxy.

Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and salts and prodrugs thereof:



(IIB)

wherein R¹¹, R¹², R¹³ and R¹⁶ are as defined with reference to formula IIA above.

Specific compounds within the scope of the present invention include:

2-amino-4-(1-benzyl-4-piperidinyl)-6-(4-chlorophenyl)pyrimidine;

2-amino-6-(4-chlorophenyl)-5-methyl-4-[1-(2-phenylethyl)-4-piperidinyl]pyrimidine;

35

- 10 -

2-amino-5-methyl-6-phenyl-4-[1-(2-phenylethyl)-4-piperidinyl]pyrimidine;
2-chloro-5-methyl-6-phenyl-4-[1-(2-phenylethyl)-4-piperidinyl]pyrimidine;
5 2-amino-4-[1-(3-cyanobenzyl)-4-piperidinyl]-5-methyl-6-phenylpyrimidine;
and salts and prodrugs thereof.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, 15 ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-20 monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a 25 pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a 30 compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout 35 the composition so that the composition may be readily subdivided into equally effective unit dosage forms such

- 11 -


as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the 5 present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, 10 the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A 15 variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

20 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils 25 such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium 30 carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.


In the treatment of schizophrenia, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and 35 especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

- 12 -

The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV or a salt thereof, e.g. the hydrochloride
5 salt:



(III)



(IV)

wherein Q, R¹ and A are as defined above, and R²⁰
15 corresponds to the group R² as defined above or
represents a precursor group thereto; in the presence of
a base; followed, where required, by conversion of the
precursor group R²⁰ into the desired group R².



The reaction between compounds III and IV is
20 conveniently carried out by heating the reactants in a
suitable solvent, typically at the reflux temperature.
The base employed will suitably be a C₁₋₄ alkoxide salt,
in which case the reaction is conveniently effected in
the corresponding C₁₋₄ alkanol as solvent. Typically,
25 the reaction may be carried out in the presence of
approximately two equivalents of sodium isopropoxide,
utilising isopropanol as the solvent.

Where R² in the final product of formula I
represents a group which is capable of being carried
30 intact through the conditions of the reaction between
compounds III and IV, for example C₁₋₆ alkyl or amino,
then the substituent R²⁰ in the intermediates of formula
IV will suitably correspond to the desired group R².
Where, on the other hand, the group R² in the final
35 product of formula I is a more reactive group, such as
halogen, then the substituent R²⁰ in compound IV will

- 13 -

advantageously represent a suitable precursor to the desired group R². By way of illustration, a product of formula I wherein R² is chloro will conveniently be obtained by reacting compound III with a compound of formula IV wherein R² is amino, and subsequently treating the compound of formula I wherein R² is amino thereby obtained with antimony trichloride and t-butyl nitrite, typically in dichloromethane at a temperature in the region of 0°C.

The compounds of formula III above may be prepared by reacting a carboxylic acid of formula V, or an activated derivative thereof, with two equivalents of a metal enolate of formula VI:



(V)

(VI)

wherein R¹ and A are as defined above, Q¹ corresponds to the moiety Q as defined above or represents a precursor thereto protected on the nitrogen atom, and M represents a metal capable of providing a suitable counterion for the enolate anion; followed, where required, by removal of the N-protecting group from the moiety Q¹; and subsequently, if necessary, attachment to the nitrogen atom thereby deprotected of an appropriate substituent by standard means to afford a product containing the desired moiety Q.

For example, the substituent Q¹ in compound V may represent a moiety of formula Qa to Qe as defined above, in which R⁷ is hydrogen and R⁶ represents an N-protecting group. Once the reaction between compounds V and VI is complete the N-protecting group must be

- 14 -

removed, and the desired group R⁶ subsequently attached, by conventional methods.


The metal M is suitably an alkali metal, especially lithium.

5 The activated derivative of the carboxylic acid V is suitably the compound formed by reaction between the carboxylic acid V and 1,1'-carbonyldiimidazole, conveniently in tetrahydrofuran.

10 Where the substituent Q¹ represents a precursor to the moiety Q protected on the nitrogen atom, the N-protecting group is suitably an alkoxy carbonyl moiety such as t-butoxycarbonyl (BOC), in which case the N-protecting group can conveniently be removed subsequently as necessary by treatment under acidic 15 conditions, e.g. stirring in hydrochloric acid or trifluoroacetic acid.

20 The reaction between compound V, or the activated derivative thereof, and compound VI is suitably carried out in a solvent such as tetrahydrofuran, commencing at -78°C with warming to room temperature.

The metal enolate of formula VI is ideally prepared by reacting the corresponding carbonyl compound of formula VII:



(VII)

wherein R¹ and A are as defined above; with a non-nucleophilic base such as lithium diisopropylamide, suitably in tetrahydrofuran at -78°C.

35 Where they are not commercially available, the starting materials of formula IV, V and VII may be prepared by standard methods well known from the art.

- 15 -

It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, as noted above, a compound of formula I wherein R² is amino initially obtained may be converted into a compound of formula I wherein R² is chloro by treatment with antimony trichloride and t-butyl nitrite, typically in dichloromethane at a temperature in the region of 0°C.

Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The

- 16 -

protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

5 The compounds useful in this invention potently inhibit [³H]-spiperone binding to human dopamine D₄ receptor subtypes expressed in clonal cell lines.

[³H]-Spiperone Binding Studies

10

Clonal cell lines expressing the human dopamine D₄ receptor subtype were harvested in PBS and then lysed in 10 mM Tris-HCl pH 7.4 buffer containing 5 mM MgSO₄ for 20 min on ice. Membranes were centrifuged at 50,000g for 15 min at 4°C and the resulting pellets resuspended in assay buffer (50 mM Tris-HCl pH 7.4 containing 5 mM EDTA, 1.5 mM CaCl₂, 5 mM MgCl₂, 5 mM KCl, 120 mM NaCl, and 0.1% ascorbic acid) at 20 mg/ml wet weight. Incubations were carried out for 60 min at room temperature (22°C) in the presence of 0.05-2 nM [³H]-spiperone or 0.2 nM for displacement studies and were initiated by addition of 20-100 µg protein in a final assay volume of 0.5 ml. The incubation was terminated by rapid filtration over GF/B filters presoaked in 0.3% PEI and washed with 10 ml ice-cold 50 mM Tris-HCl, pH 7.4. Specific binding was determined by 10 µM apomorphine and radioactivity determined by counting in a LKB beta counter. Binding parameters were determined by non-linear least squares regression analysis, from which the inhibition constant K_i could be calculated for each test compound.

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [³H]-spiperone from the human dopamine D₄ receptor subtype of below 1.5 µM.

EXAMPLE 1a) 4-[1-(1,3-Dioxo-3-phenyl-2-methylpropyl)piperidine hydrochloride

A solution of *n*-butyllithium in hexanes (1.6M, 125cm³) was added at 10°C to a stirred solution of diisopropylamine (28cm³) in dry tetrahydrofuran (300cm³) under an argon atmosphere. The resulting solution of lithium diisopropylamide was cooled to -78°C and propiophenone (26cm³) was added dropwise. The solution was stirred at -78°C for 1 hour. Meanwhile,
5 1,1-carbonyldiimidazole (17.0g) was added portionwise at 0°C to a stirred solution of 1-*tert*-butyloxycarbonylpiperidine-4-carboxylic acid (23.0g) in dry tetrahydrofuran (200cm³). Moderate effervescence was observed as the solids dissolved to form a pale yellow solution. The solution was transferred *via* 10 cannula to the enolate solution, cooled to -78°C. The resulting thick, white suspension was stirred at -78°C for 45 minutes and then warmed to room temperature. The suspension was poured into saturated aqueous ammonium chloride (500cm³) and the mixture was extracted with ethyl acetate (2 x 200cm³). The 15 combined organic phases were dried (MgSO₄), filtered and concentrated to give a yellow oil. The oil was redissolved in ethyl acetate (100cm³) and an ice-cold saturated solution of hydrogen chloride in ethyl acetate (200cm³) was added. The resulting suspension was cooled to 4°C for 24 hours. The solvent volume 20 was reduced to 100cm³ by evaporation, producing a white solid. The solid was collected and dried at room temperature *in vacuo* to give the *title compound* (21.0g, 75%); δ_H (360MHz; d₆-DMSO) 25 1.26 (3H, d, *J* 7, CH₃), 1.53-1.63 (2H, m, 2 x NCH₂CH_AH_B), 1.90-2.05 (2H, m, 2 x NCH₂CH_AH_B), 2.82-2.94 (3H, m, 2 x NCH_AH_B and NCH₂CH₂CH), 3.02-3.08 (2H, m, 2 x NCH_AH_B), 5.13 [1H, q, 30 *J* 7, COCH(CH₃)CO], 7.58 (2H, dd, *J* 7.5 and 7.5, 2 x ArH_{m to CO}), 7.68 (1H, m, ArH_{p to CO}), 8.01 (2H, d, *J* 7.5, 2 x ArH_{o to CO}), 9.11

and 9.34 (1H and 1H, 2 x broad s, +NH₂); *m/z* (Cl⁺; NH₃) 246 (M⁺ + H; 100%).

5 b) 1-(2-Phenylethyl)-4-[1-(1,3-dioxo-3-phenyl-2-methylpropyl)]piperidine hydrochloride

4-[1-(1,3-Dioxo-3-phenyl-2-methylpropyl)]piperidine hydrochloride (10.0g) was partitioned between aqueous potassium carbonate (1M, 50cm³) and dichloromethane (2 x 100cm³). The organic extracts were dried (MgSO₄) filtered and concentrated to give the free base as a yellow oil. The oil was redissolved in dry dimethylformamide (200cm³) and 1-(2-bromoethyl)benzene (5.3cm³) and triethylamine (5.2cm³) were added. The solution was heated at 50°C under an argon atmosphere for 18 hours. The solution was cooled to room temperature and poured into saturated aqueous sodium hydrogen carbonate (500cm³) prior to extraction with diethyl ether (2 x 200cm³). The combined organic extracts were dried (MgSO₄), filtered and concentrated. The resulting yellow oil was redissolved in ethyl acetate (50cm³) and a saturated solution of hydrogen chloride in ethyl acetate (150cm³) was added. Solvent was removed by evaporation and the residues were triturated with diethyl ether to give the *title compound* as a white solid (9.95g, 72%); δ_H (360MHz; d₆-DMSO) 1.27 (3H, d, *J* 7, CH₃), 1.80-2.10 (4H, m, 2 x NCH₂CH₂), 2.84-3.29 (7H, m, 2 x NCH_AH_B, NCH₂CH₂Ph and NCH₂CH₂CH), 3.55-3.58 (2H, m, 2 x NCH_AH_B), 5.17 [1H, q, *J* 7, COCH(CH₃)CO], 7.21-7.35 (5H, m, Ph), 7.58 (2H, dd, *J* 7.5 and 7.5, 2 x ArH_m to CO), 7.70 (1H, t, *J* 7.5, ArH_p to CO) and 8.03 (2H, d, *J* 7.5, 2 x ArH_o to CO); *m/z* (Cl⁺; NH₃) 350 (M⁺ + H; 100%).

30 c) 2-Amino-4-[1-(2-phenylethyl)-4-piperidinyl]-6-phenyl-5-methylpyrimidine

A mixture of sodium (0.18g) and dry propan-2-ol (15cm³) was heated at reflux under an argon atmosphere until the sodium

had dissolved. The solution was cooled and guanidine hydrochloride (0.74g) was added. The suspension was heated at reflux for 1 hour and then cooled to room temperature.

Meanwhile, 1-(2-phenylethyl)-4-[1-(1,3-dioxo-3-phenyl-2-methylpropyl)]piperidine hydrochloride (3.00g) was partitioned between aqueous potassium carbonate (1M, 50cm³) and dichloromethane (2 x 50cm³). The combined organic extracts were dried (MgSO₄), filtered and concentrated to give the free base as a yellow oil. The oil was redissolved in dry propan-2-ol (5cm³) and the solution was added to the previously prepared suspension. The mixture was heated at reflux under argon for 1.5 hours and was then diluted with water (20cm³) and cooled to 0°C. The resulting white solid was collected. The material was recrystallised from ethanol-water to give the *title compound* (0.90g, 31%) as white crystals, m.p. 199-200°C. Found: C, 77.72; H, 7.48; N, 14.86. C₂₄H₂₈N₄ requires C, 77.38; H, 7.58; N, 15.04%. δ_H (360MHz; d₆-DMSO) 1.65 (2H, apparent d, J 12, 2 x NCH₂CH_AH_B), 1.84 (2H, apparent q, J 12, 2 x NCH₂CH_AH_B), 2.02-2.08 (5H, m, 2 x NCH_AH_B and CH₃), 2.54 (2H, t, J 8, NCH₂CH₂Ph), 2.74-2.78 (3H, m, NCH₂CH₂Ph and NCH₂NCH_AH_B), 6.23 (2H, broad s, NH₂), 7.16-7.30 (5H, m, Ph) and 7.41-7.44 (5H, m, Ph); m/z (Cl⁺; NH₃) 373 (M⁺ + H; 100%).

EXAMPLE 2

25 2-Chloro-4-[1-(2-phenylethyl)-4-piperidinyl]-6-phenyl-5-methylpyrimidine

A solution of antimony (III) chloride (0.61g) in dry dichloromethane (2cm³) was added to a solution of 2-amino-4-[1-(2-phenylethyl)-4-piperidinyl]-6-phenyl-5-methylpyrimidine (0.5g) in dry dichloromethane (13cm³) at 0°C under argon. The resulting white suspension was stirred vigorously while *tert*-butyl nitrite (90%, 0.75cm³) was added dropwise. The mixture

was stirred at 0°C for 3.5 hours and then poured into saturated aqueous sodium hydrogencarbonate solution (25cm³). The mixture was diluted with dichloromethane (25cm³) and filtered. The filtrate was separated and the aqueous layer was extracted with 10% methanol-dichloromethane (2 x 25cm³). The combined organic extracts were dried (MgSO₄), filtered and concentrated to give the crude 2-chloropyrimidine as a yellow solid (0.40g, 75%). A sample (0.10g) of the crude material was recrystallised from ethanol-water to give the *title compound* (0.03g) as a white powder, m.p. 170-171°C. Found: C, 73.65; H, 6.67; N, 10.40. C₂₄H₂₈N₃Cl + 0.05(CH₃CH₂OH) requires C, 73.42; H, 6.72; N, 10.66%. δ_H (360MHz; d₆-DMSO) 1.77-1.86 (4H, m, 2 x NCH₂CH₂), 2.01 (2H, apparent td, J 11 and 4, 2 x NCH_AH_B), 2.29 (3H, s, CH₃), 2.55 (2H, t, J 8, NCH₂CH₂Ph), 2.77 (2H, t, J 8, NCH₂CH₂Ph), 2.96-3.02 (1H, m, NCH₂CH₂CH), 3.07 (2H, apparent d, J 11, 2 x NCH_AH_B), 7.16-7.31 (5H, m, Ph) and 7.51-7.58 (5H, m, Ph); m/z (CI⁺; NH₃) 392 (M⁺ +H; 100%).

EXAMPLE 3

20 2-Amino-4-[1-(2-phenylethyl)-4-piperidinyl]-6-(4-chlorophenyl)-5-methylpyrimidine

White granules, m.p. 179-180°C (from DMF-water). Found: C, 70.62; H, 6.61; N, 13.58. C₂₄H₂₇N₄Cl requires C, 70.83; H, 6.69; N, 13.77%. δ_H (360MHz; d₆-DMSO) 1.65 (2H, apparent d, J 12, 2 x NCH₂CH_AH_B), 1.83 (2H, apparent q, J 12, 2 x NCH₂CH_AH_B), 2.02-2.08 (5H, m, CH₃ and 2 x NCH_AH_B), 2.54 (2H, t, J 8, NCH₂CH₂Ph), 2.73-2.81 (3H, m, NCH₂CH₂Ph and NCH₂CH₂CH), 3.04 (2H, apparent d, J 11, 2 x NCH_AH_B), 6.28 (2H, s, NH₂), 7.16-7.30 (5H, m, Ph) and 7.46-7.52 (4H, m, ArH); m/z (CI⁺; NH₃) 407 (M⁺ +H; 100%).

EXAMPLE 42-Amino-4-(1-benzyl-4-piperidinyl)-6-(4-chlorophenyl)pyrimidine

White granules, m.p. 251-253 (from EtOH). [Found: C, 57.46; H, 5.53; N, 12.03. $C_{21}H_{25}N_4Cl_2+0.4(H_2O)$ requires C, 57.56; H, 5.67; N, 12.21%]; δ_H (360MHz; d_6 -DMSO) 2.10-2.20 (4H, m, 2 x NCH_2CH_2), 2.86-3.24 (3H, m, 2 x $NCH_AH_BCH_2$ and NCH_2CH_2CH), 3.42-3.45 (2H, m, 2 x $NCH_AH_BCH_2$), 4.32 and 4.49 (2H, 2 x d, J 5, NCH_2Ph), 7.24 (1H, s, $C=CH$), 7.46-7.48 (3H, m, 3 of Ph), 7.62-7.72 (4H, m, 2 of Ph and 2 x $ArH_{o\ to\ Cl}$), 8.15 and 8.23 (2H, 2 x d, J 8, 2 x $ArH_{m\ to\ Cl}$), 11.03 and 11.16 (1H, 2 x broad s, $+NH$); m/z (CI $^+$; NH₃) 379 (M^++H ; 100%).

EXAMPLE 5

15

2-Amino-4-[1-(3-cyanobenzyl)-4-piperidinyl]-5-methyl-6-phenyl pyrimidine

White granules, m.p. 176°C (from ethyl acetate/petrol 60-80). [Found: C, 74.98; H, 6.55, N, 17.86. $C_{24}H_{25}N_5$ requires C, 75.17; H, 6.57; N, 18.26%]; δ_H (360MHz; d_6 -DMSO) 1.64 (2H, m), 1.87 (2H, m), 2.05 (3H, s), 2.08 (2H, m), 2.80 (1H, m), 2.89 (2H, m), 3.56 (2H, s), 6.25 (2H, br, s), 7.54-7.76 (9H, m); m/z (CI $^+$; NH₃) 384 (M^++H ; 100%).


25

- 22 -

CLAIMS:

1. A compound of formula I, or a salt thereof or a prodrug thereof:

5



(I)

wherein


15 Q represents a substituted five- or six-membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole heteroatom and is linked to the pyrimidine ring via a carbon atom;

20 R¹ represents hydrogen, halogen, C₁₋₆ alkyl, hydroxy or C₁₋₆ alkoxy;


R² represents hydrogen, halogen, C₁₋₆ alkyl, -OR^a or -NR^aR^b; and

A represents a group of formula (i), (ii) or (iii):


25



(I)



(II)



(III)

35 in which Z represents oxygen, sulphur or NH; R³, R⁴ and R⁵ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano,


- 23 -

trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

5 R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

2. A compound as claimed in claim 1 represented by formula IIIA, and salts and prodrugs thereof:

10



(IIA)

20 wherein

R¹¹ represents hydrogen or C₁₋₆ alkyl;


R¹² represents hydrogen, halogen, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, amino, C₁₋₆ alkylamino or di(C₁₋₆)alkylamino;

25 R¹³ represents hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy or C₂₋₆ alkylcarbonyl; and

30 R¹⁶ represents C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl or aryl(C₁₋₆)alkyl, any of which groups may be optionally substituted.

3. A compound as claimed in claim 1 represented by formula IIB, and salts and prodrugs thereof:

- 24 -



(11B)

wherein R¹¹, R¹², R¹³ and R¹⁶ are as defined in claim 2.

4. A compound as claimed in claim 2 or claim
3 wherein R¹³ represents hydrogen, chloro, methyl, ethyl,
15 isopropyl or methoxy.

5. A compound as claimed in any one of claims
2 to 4 wherein R¹⁶ represents allyl, cyclopropylmethyl,
cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl,
20 dichlorobenzyl, methoxy-benzyl, nitro-benzyl,
cyano-benzyl, naphthylmethyl, phenethyl or phenylpropyl.

6. A compound as claimed in claim 1 selected
from:
25 2-amino-4-(1-benzyl-4-piperidinyl)-6-(4-
chlorophenyl)pyrimidine;
2-amino-6-(4-chlorophenyl)-5-methyl-4-[1-(2-phenylethyl)-
4-piperidinyl]pyrimidine;
2-amino-5-methyl-6-phenyl-4-[1-(2-phenylethyl)-4-
30 piperidinyl]pyrimidine;
2-chloro-5-methyl-6-phenyl-4-[1-(2-phenylethyl)-4-
piperidinyl]pyrimidine;
2-amino-4-[1-(3-cyanobenzyl)-4-piperidinyl]-5-methyl-6-
phenylpyrimidine;
35 and salts and prodrugs thereof.

- 25 -


7. A pharmaceutical composition comprising a compound as claimed in any one of the previous claims in association with a pharmaceutically acceptable carrier.

5 8. A compound as claimed in any one of claims 1 to 6 for use in therapy.


10 9. The use of a compound as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment and/or prevention of disorders of the dopamine system.

15 10. A process for the preparation of a compound as claimed in claim 1 which comprises:

15 (A) reacting a compound of formula III with a compound of formula IV or a salt thereof:



(III)



(IV)

wherein Q, R¹ and A are as defined in claim 1, and R²⁰ corresponds to the group R² as defined in claim 1 or represents a precursor thereto; in the presence of a base; followed, where required, by conversion of the precursor group R²⁰ into the desired group R²; and

35 (B) subsequently, where required, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

- 26 -

11. A method for the treatment and/or prevention of disorders of the dopamine system, which method comprises administering to a patient in need of such treatment an effective amount of a compound as
5 claimed in any one of claims 1 to 6.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 94/00999

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D401/04 C07D409/14 C07D401/14 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO,A,94 10162 (MERCK SHARP & DOHME LIMITED) 11 May 1994 see the whole document ---	1-10
E	WO,A,94 10145 (MERCK SHARP & DOHME LTD.) 11 May 1994 see the whole document ---	1-10
A	J. MED. CHEM. vol. 30 , 1987 pages 2099 - 2104 I VAN WIJNGAARDEN ET AL '2-Phenylpyrroles as conformationally restricted benzamide analogues' *see especially compound no 1* ---	1-10
A	EP,A,0 259 930 (DUPHAR INTERNATIONAL RESEARCH B.V.) 16 March 1988 ---	1-10 -/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'&' document member of the same patent family

2

Date of the actual completion of the international search

11 August 1994

Date of mailing of the international search report

26.08.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 94/00999

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 168 262 (FUJISAWA PHARMACEUTICAL CO. LTD.) 15 January 1986 ---	1-10
A	WO,A,85 00168 (SANOFI) 17 January 1985 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/GB 94/00999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9410162	11-05-94	AU-B-	5341394	24-05-94
WO-A-9410145	11-05-94	AU-B-	5341494	24-05-94
EP-A-0259930	16-03-88	AU-B- AU-A- DE-A- JP-A- US-A- ZA-A-	609415 7819187 3776611 63077856 4791132 8706749	02-05-91 17-03-88 19-03-92 08-04-88 13-12-88 14-03-88
EP-A-0168262	15-01-86	JP-A- US-A-	61044872 4725600	04-03-86 16-02-88
WO-A-8500168	17-01-85	FR-A- AU-A- EP-A,B JP-T- US-A-	2547821 3060384 0151140 60501655 4602015	28-12-84 25-01-85 14-08-85 03-10-85 22-07-86